Literature DB >> 28121504

Romosozumab Treatment in Postmenopausal Osteoporosis.

Felicia Cosman1, Daria B Crittenden2, Andreas Grauer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28121504     DOI： 10.1056/NEJMc1615367

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.

Authors:  Eric Hesse; Saskia Schröder; Diana Brandt; Jenny Pamperin; Hiroaki Saito; Hanna Taipaleenmäki
Journal:  JCI Insight       Date:  2019-04-09

2.  Osteoporosis: Romosozumab to rebuild the foundations of bone strength.

Authors:  Serge L Ferrari
Journal:  Nat Rev Rheumatol       Date:  2018-01-25       Impact factor: 20.543

3.  Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosis.

Authors:  Tae-Keun Ahn; Kyoung-Tae Kim; Hari Prasad Joshi; Kwang Hwan Park; Jae Won Kyung; Un-Yong Choi; Seil Sohn; Seung-Hun Sheen; Dong-Eun Shin; Soo-Hong Lee; In-Bo Han
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.